News

Opus Genetics Receives FDA Clearance to Advance RDH12 Gene Therapy into Clinical Development

We are deeply encouraged by Opus Genetics’ FDA clearance to begin clinical development of OPGx-RDH12, an investigational gene therapy for RDH12-associated childhood blindness, developed in collaboration with patient organisations to advance a potential treatment for this rare inherited retinal disease.

This is a major milestone for the retina community. By bringing patient organisations and researchers together to share funding, knowledge and risks, this collaborative approach is helping advance research towards potential treatments. Putting families at the heart of research helps ensure their needs and experiences are heard and could inspire other rare disease communities to follow a similar path.

We know how tirelessly Silvia Cerolini has worked for this moment.

Well done, Silvia, Eyes on the Future, RDH12 Fund for Sight and all at the Global RDH12 Alliance and Opus Genetics on this important achievement!

➡️ Read More Here

Newsletter

Stay connected with Retina International

Sign up for the latest research, advocacy news and events.

Retina International